ClinicalTrials.gg
RecruitingNCT06712602Updated Sep 16, 2026

PT150 Drug for Use in Alcohol Use Disorder

A Phase 1 interventional study of alcohol and Stress-Induction in Alcohol Use Disorder, sponsored by Pop Test Oncology LLC. Recruiting at 1 site in United States. Open to participants aged 21 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-09-16.

Sponsored by Pop Test Oncology LLC · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
21 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,073 studies in Alcoholism with a site in United States — 187 open to participants now, 227 under way, 15 of them phase 3. Alcoholism · United States.

Planned enrollment
726th of 989
34 · median 80
Started
2025
with 55 others
Phase 1
102 of 1,073
22 open now
Primary completion
2028-07
later than 159 of 226 live
Registered
984th of 1,073
by date

Among the 1,073 studies in Alcoholism with a site in United States, this one is the 726th largest by planned enrollment of the 989 interventional ones that give a count, is one of 56 that started in 2025, is one of 102 in phase 1, reaches primary completion later than 159 of the 226 other live ones, and was the 984th registered.

Alcoholism

1,676 studies on the registry are indexed under Alcoholism; 331 are open to participants now.

Browse Alcoholism studies →

Open to participants now

187 of the 1,073 studies in Alcoholism with a site in United States are open now. Recruiting first, the newest first:

182 more — sign in →

All 187 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 237 Alcoholism studies recruiting now, 84 (35%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.

This study: 21 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,073 studies in Alcoholism with a site in United States, or all of them as a file.
02

Study summary

The goal of this study is to learn if PT150 can reduce the behavioral and physical effects of stress, alcohol, and alcohol use in people with alcohol use disorder.

Read the detailed description

The Investigators will conduct behavioral testing in an individual room with a lounge chair and laptop computer for completing the questionnaires, along with supplies for the bilateral foot CPT. Computerized data collection increases the accuracy of data collection and efficiency of data management. Participants will remain seated in the lounge chair for the duration of the session. Procedures Specific to the Stress-Induction Session Stress-Induction. The stress-induction procedure is the Cold Pressure Test [CPT]) stressor. The bilateral foot CPT requires participants to submerge both feet in ice-cold water (2-4°C) for 3 minutes . The Investigators will inform participants the cold water, while painful, will not cause tissue damage. The Investigators will further instruct participants a same-sex research assistant and medical staff will monitor them for their safety. Participants will not know how much time remains in the procedure (i.e., no clocks, watches or electronic devices allowed). The Investigators will record behavioral (i.e., alcohol demand, craving, mood, and subjective effects) and neuroendocrinological (i.e., salivary cortisol) responses as noted in Table 2. Stress-induction procedures are safe, and reliably elicit behavioral and neuroendocrinological responses in controls and patients with AUD, including those with PTSD. The Investigators will demonstrate the internal validity of the stress-induction procedure using a single visual analog scale anchored with adjective modifiers (0=Not at All to 100=Extremely): How STRESSED are you right now? Alcohol Demand. The Investigators will use a purchasing task to measure alcohol demand. Participants will report hypothetical consumption of their preferred alcohol beverage across a range of prices given they can only get the drinks from a single source and would have to consume all of them in a single sitting. Single doses of their preferred alcohol beverage will be available across 14 prices (i.e., $0.00 [Free], $0.01 $0.03, $0.30, $1, $3, $10, $30, $100, $300, $1,000). All choices will be hypothetical, and the Investigators will not administer any alcohol during this task. Alcohol purchasing tasks are sensitive to stress manipulations. Craving and Mood Questionnaires. The Investigators will use two instruments to assess craving. First, the Investigators will use the Alcohol Urge Questionnaire. Second, the Investigators use a set of four unidimensional visual analog scales: 1) How strong is your craving to drink alcohol? 2) If I could drink alcohol now, I would drink it; 3) It would be hard to turn down a drink right now; and 4) Having a drink would make things just perfect. The Investigators will use the short form of the Profile of Mood States. The POMS-SF uses five-point scales (Not at All to Extremely) to measure six aspects of mood (Tension or Anxiety, Anger or Hostility, Vigor or Activity, Fatigue or Inertia, Depression or Dejection, Confusion or Bewilderment). The Alcohol Urge Questionnaire and POMS-SF are sensitive to stress manipulations. Salivary Cortisol. The Investigators will collect salivary cortisol samples before and periodically after the stress-induction procedure for 120 minutes using cotton swab Salivettes®. The Investigators will store the samples at room temperature until the end of the experimental session and then at -80°C until analyzed using the standard University of Kentucky laboratory assessment. Safety Measures. The Investigators will record heart rate and blood pressure before the stress-induction procedure and afterwards for 120 mins. Procedures Specific to the Alcohol Administration Session Alcohol Challenge. During this session, participants will receive a single administration of alcohol (0.5 g/kg) mixed with lemon lime soda. The Investigators will instruct participants to consume the drink within 5 min. The Investigators will assess the behavioral and physiological effects before alcohol administration (Baseline) and afterwards for 120 mins using the measures described below (Table 2). The Investigators selected this dose because, in our experience, it is behaviorally active, well tolerated, and raises breath alcohol concentration ([BAC] for approximately 2.5-3.0 hours. Alcohol Demand. The Investigators will use the purchasing task described above but modify it to reflect the hypothetical choices between the drink they sampled across varying prices. The Investigators have shown hypothetical alcohol choices are an orderly function of price and are sensitive to Section 9 Page 5 of 15 90580 putative pharmacotherapies. Craving, Mood, and Subjective-Effect Questionnaires. The Investigators will use four standardized subjective-effects questionnaires to measure various aspects of mood and alcohol effects: 1) Biphasic Alcohol Effects Scale; 2) Subjective High Assessment Scale; 3) Alcohol Urge Questionnaire; and 4) of Mood States Short Form. The Investigators will use the set of 4 unidimensional visual analog scales described above. The Investigators will also use a locally developed 10-item Drug Effect Questionnaire. Participants rate each item using visual analog scales anchored with adjective modifiers (0=Not at All to 100=Extremely) to rate the effects of the drink: Any Effects, Bad Effects, Drunk, Good Effects, Like Effects, Performance Impaired, Performance Improved, Stimulated, Talkative-Friendly, and Willing to Take Again. Performance Measure. The Investigators will assess motor coordination using a grooved pegboard task (Lafayette Instruments, Lafayette, IN). During this task, participants place pegs into keyhole-shaped holes. The grooved pegboard contains a rectangular metal surface with 25 holes arranged in five rows of five holes. Each of the holes has a rounded side and smaller square side (a groove). The orientation of the groove in each hole varies so that no two adjacent holes have the same orientation. Each peg is 3 mm in diameter and 2.5 cm long and has a rounded side and grooved side. Pegs fit into the holes like a key would fit into a lock. Participants are required to pick up pegs one at a time and place them in holes. They fill one row at a time and work from left to right. A trial on the grooved pegboard task was completed when all 25 holes were filled, and the time to complete a trial was the measure of interest. A grooved pegboard test consisted of four trials, and the time to complete each of the trials was averaged to calculate the measure of motor coordination. The grooved pegboard task is sensitive to the effects of. Salivary Cortisol. The Investigators will collect salivary cortisol samples before and periodically after alcohol administration as shown in Table 2. Safety Measures. The Investigators will record heart rate, blood pressure, and BAC levels before administering the ALC dose and afterwards for 120 mins. Procedures Specific to Assessing Alcohol Use, Craving, and Stress in the Natural Ecology Participants will access a REDCap survey daily to report the number of drinks consumed in the past day and to complete the Alcohol Urge Questionnaire, POMS-SF, Perceived Stress Questionnaire, and the single-item sleep quality questionnaire. The Investigators will also use the REDCap survey to monitor adverse events. The Investigators will calculate the number of heavy drinking days for each participant (males = 5 standard drinks, females =4 standard drinks; NIAAA, 2017). The Investigators have used similar procedures in the past to measure the effects of putative pharmacotherapies for AUD in the natural environment. Follow-Up Visit and Discharge from Study, the Investigators will schedule participants for a follow-up visit approximately one week after the last experimental session (i.e., those completing the study) or the final session completed (i.e., those not completing the study; Table 1). During this visit the Investigators will gather much of the same information recorded during the Pre-Participation Screening (e.g., drug-use questionnaire, heart rate and blood pressure, urine drug test). The Investigators will also query participants regarding how they used payments dispersed after their final experimental session. Participants will complete the Perceived Research Burden Assessment and Coercion Assessment Scale during the follow-up visit to measure their overall study experience. Data Analysis, the Investigators will analyze data as raw scores unless noted otherwise. The Investigators will replace participants who do not complete the study until the Investigators accrue 34 completers to ensure sufficient statistical power. Statistical significance refers to p equal to or less than 0.05. The Investigators predict: 1) stress induction will increase cortisol, alcohol demand and negative mood, and PT150 will attenuate these responses, 2) alcohol will increase alcohol demand and produce prototypical subjective effects and PT150 will attenuate these effects, and 3) PT150 will decrease drinking, craving, and stress in the natural ecology. Exploratory analyses will determine if: 1) responses/changes differ in females and males; 2) baseline cortisol or stress levels predict behavioral or neuroendocrinological responses to stress and attenuation by PT150; and 3) behavioral and neuroendocrinological responses and attenuation by PT150 during the stress-induction session predict changes in the natural ecology. Stress-Induction Session (Specific Aim 1). The Investigators will analyze data from the purchase task (i.e., alcohol demand) using derived and curve-observed measures. Derived measures include demand intensity (Q0; consumption at unconstrained price) and demand elasticity (a measure of sensitivity of consumption to changes in price) and will be computed using the exponential demand equation LogQ=Log Q0+k(e\^(-a Q0C)-1. The independent variable C is cost (price/dose), the dependent variable Q is consumption (doses purchased at a particular price), and the scaling parameter k indicates the range of LogQ in the observed data. Free parameters are Q0 (demand intensity) and a (demand elasticity). Should the Investigators observe zero-dense data, the Investigators will consider using a modified exponentiated form of the demand equation. Outcome measures include Pmax (price at maximum consumption), Omax (maximum consumption) and breakpoint (Breakpoint-1; the price of last non-zero demand), Q0 (demand intensity) and a (demand elasticity). Behavioral (e.g., alcohol demand, craving, mood, and subjective effects) and neuroendocrinological (e.g., salivary cortisol) outcomes from the stress-induction session will be analyzed with generalized linear mixed models (GLMM), allowing us to statistically account for the longitudinal nature of the data. GLMM are virtually identical to repeated measures ANOVA when no data are missing but can appropriately handle non-normal outcomes and allow the specification of numerous covariance structures. The Investigators will enter PT150 dose (0, 450, 900 mg), Time (Baseline, 0, 10, 20, 30, 45, 60, 90, 120) minutes after stress-induction or alcohol administration), and their interaction into the models as predictors. The Investigators will use severity of AUD (moderate, severe) and baseline Section 9 Page 6 of 15 90580 measures of quantity and frequency (e.g., drinks/drinking day, drinking days/month) as a time-invariant predictor in all models to control for levels of alcohol use. The Investigators will use design matrix for testing custom hypotheses regarding the outcome response profiles over time (e.g., linear, quadratic, or piecewise change) and whether these trajectories differ by PT150 dose to infer a significant attenuation of the effects of stress-induced responses if the main effect of PT150 or the interaction of PT150 and Time attains statistical significance. If the interaction of PT150 and Time attains statistical significance, the Investigators will use Tukey's HSD corrected for multiple comparisons to determine the locus of the effect by making appropriate pair-wise comparisons. The Investigators will also calculate area-under-the curve (AUC) using the trapezoidal method for appropriate measures (e.g., cortisol) and analyze these data similarly excluding Time from the model (Scheff et al., 2011). Alcohol Challenge Session (Specific Aim 2). The Investigators will analyze data (alcohol demand, craving, subjective effects, breath-alcohol) from the ALC challenge session as described above. Alcohol Use, Craving and Stress in the Natural Ecology (Specific Aim 3). The Investigators will analyze alcohol use in the natural ecology as total number of drinks and heavy drinking days during each maintenance phase. The Investigators will average data from the Alcohol Urge Questionnaire, POMS-SF, single-item sleep quality questionnaire, and Perceived Stress Questionnaire across maintenance days on each PT150 dose. The Investigators will analyze these data with GLMM with PT150 (0, 450, 900 mg/day) as the sole within-subject factor. The Investigators will infer a significant increase or decrease if the main effect of the PT150 attains statistical significance. If the omnibus test is significant, the Investigators will use Tukey's HSD corrected for multiple comparisons to make comparisons between means. Exploratory Analysis (Exploratory Aims). The Investigators will use multivariate latent curve models to concurrently model the same longitudinal outcomes collected following stress-induction and the alcohol sample dose to compare the growth processes (i.e., intercept, slope) of these outcomes. Sex is the primary biological variable of interest because the effects of selective GR antagonists differed in males and females in preclinical. Safety and Adverse Events. The Investigators will use GLMM with PT150 group (0, 450, 900 mg/day) and Time (Pre- versus Post-Participation). The Investigators will infer significant changes if the main effects of PT150 group or Time, as well as the interaction of these variables, attain statistical significance. If the interaction of PT150 and Time attains statistical significance, the Investigators will use Tukey's HSD corrected for multiple comparisons with the mean square error term to make appropriate pair-wise comparisons. The Investigators will record adverse event frequency during maintenance as a count variable (i.e., number of side effects reported). Comparison by dose condition will use GLMM with a log link (i.e., Poisson distribution) and dose as a time-varying covariate. Power and Sample Size. The Investigators used the results of a previous human laboratory study in participants with AUD to estimate an appropriate sample size for detecting an effect of GR antagonism on experimentally induced increases in craving. Mifepristone reduced experimentally induced increases in alcohol craving (mean Cohen's f = 0.32). The Investigators used the results of a meta-analysis of human laboratory studies of alcohol self-administration and craving to determine an appropriate sample size for the proposed study to detect whether PT150 attenuates the acute pharmacodynamic effects of alcohol. Naltrexone decreased alcohol consumption and self-reported craving relative to placebo with an average estimated effect size of Hedges' g=-0.28. The previous study described above with mifepristone reported reductions in drinking in the natural ecology with an average estimated effect size of Cohen's f = 0.26. Considering the crossover design and 3 levels of PT150 (0, 450, 900 mg/day), enrolling 34 participants will provide power >0.85 (alpha=0.05, nQuery®) for us to detect an effect of PT150 on experimentally-induced stress responses (Specific Aim 1), the pharmacodynamic effects of alcohol (Specific Aim 2), and alcohol use in the natural ecology (Specific Aim 3) with an effect size similar to those observed previously (Cohen's f=0.25, power=0.80, alpha=0.05, nQuery®). The proposed statistical procedures (i.e., GLMM) can also accommodate missing data via maximum and quasi-likelihood estimation algorithms. The Investigators will include data available from participants who do not complete to further ensure adequate statistical power to detect the effects of PT150 on the primary outcomes. Enrolling 34 participants (17 females, 17 males) is also sufficient to determine whether the effects of PT150 differ as a function of sex. A preclinical study determined the effects of a range of doses of CORT113176, a selective GR antagonist, on alcohol self-administration in male and female (9-10/sex) rats and found a significant effect of sex. Finally, enrolling 34 participants is also sufficient to determine if baseline cortisol or stress levels predict behavioral or neuroendocrinological responses to stress and attenuation by PT150; and whether the behavioral and neuroendocrinological responses and attenuation by PT150 during the stress-induction session predict changes drink in the natural ecology (Exploratory Aims). One of the studies described above reported reductions in experimentally induced alcohol craving observed with mifepristone in the laboratory predicted reductions in the number of drinks per drinking day in the natural ecology (R2=0.11, p=0.017, Cohen's f=0.352).

03

Conditions studied

  • Alcohol Use Disorder

Browse trials for

Keywords

  • Alcohol
  • Alcohol Use Disorder
  • Alcoholism
04

Who can participate

Ages eligible
21 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Meet diagnostic criteria for AUD (moderate or severe) per the - 5th edition (DSM-5)

Not seeking treatment at the time of the study

English-speaking

Between the ages of 21 and 55 years (individuals under 21 are excluded based on the recommendations of NIAAA that alcohol should not be administered to individuals under the legal drinking age)

Abstinent from alcohol no more than 3 days per week on average

Physically and psychiatrically healthy other than the diagnoses for AUD or tobacco use disorder

, read by cardiologist, within normal limits

of 19 - 35

Using an effective form of (e.g., birth control pills, surgical sterilization, condoms, IUD, cervical cap with a spermicide or abstinence) if female

Able to abstain from ALC for 12 hours prior to sessions

No to ALC or PT150

Exclusion criteria

Exclusion Criteria:

Meet diagnostic criteria for SUDs, save nicotine, other than AUD that in the opinion of a study physician would require medical intervention (e.g., opioid use disorder) or compromise the well-being of the participant

Have abnormal blood chemistry, complete blood count or urinalysis values deemed

Have a history of serious physical disease or current physical disease (e.g., impaired cardiovascular functioning, histories of seizure, head trauma or CNS tumors)

Have a current or past history of psychiatric disorder that would interfere with participation (e.g., psychotic [schizophrenia, schizoaffective]), bipolar, major depressive disorder)

Have had suicidal ideations in the past 90 days

Pregnant or nursing

Are unwilling/unable to comply with study procedures

Participants scoring >6 on the Clinical Institute Withdrawal Assessment for Alcohol Revised (CIWA-Ar); the CIWA-Ar will be administered prior to each experimental session participants who score >6 will be excluded further participation.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
34 participants (estimated)

Study arms

  • Experimental
    PT150 with alcohol consumption then stress

    Following at least five days of maintenance on a randomized dose of PT150, participants will complete an experimental alcohol administration session. No less than 24 hours later, participants will then complete an experimental stress induction session.

    Drug: alcohol · Behavioral: Stress-Induction · Drug: PT150

  • Experimental
    PT150 with stress then alcohol consumption

    Following at least five days of maintenance on a randomized dose of PT150, participants will complete an experimental session involving stress induction. No less than 24 hours later, participants will then complete an experimental alcohol administration session.

    Drug: alcohol · Behavioral: Stress-Induction · Drug: PT150

Interventions

  • During the alcohol administration session participants will receive a single administration of alcohol (0.5 g/kg) mixed with lemon lime soda. Participants will consume the drink within 5 min.

  • BehavioralStress-Induction

    The stress-induction procedure is the Cold Pressure Test \[CPT\]) stressor. The bilateral foot CPT requires participants to submerge both feet in ice-cold water (24°C) for 3 minutes.

  • DrugPT150

    Participants will ingest PT150 (0, 225, 450 mg) twice daily (e.g., 0800, 2000h) for 5 five days prior to the conduct of the experimental sessions. The sequence of PT150 doses will be quasi-random such that participants will be maintained on the lower dose of PT150 (i.e., 225 mg twice/day) before the higher dose.

06

What researchers measure

Primary outcomes

  1. Change in salivary cortisol (alcohol)

    Salivatory samples will be collected before and periodically after the alcohol challenge procedure for 120 minutes using cotton swab salivettes.

    Time frame: Baseline, week 1, week 2, week 3, and follow up (up to 34 days)

  2. Change in salivary cortisol (stress induction)

    Salivatory samples will be collected before and periodically after the stress induction procedure for 120 minutes using cotton swab salivettes.

    Time frame: Baseline, week 1, week 2, week 3, and follow up visit (up to 34 days)

  3. Change in Alcohol Demand (stress induction)

    A drug purchasing task will be used to determine how many hypothetical doses of their preferred alcohol beverage participants would purchase across varying prices.

    Time frame: Baseline, and sessions 1 - 3 (up to 30 days)

  4. Change in Alcohol Demand (alcohol)

    A drug purchasing task will be used to determine how many hypothetical doses of the alcoholic beverage given during the session participants would purchase across varying prices.

    Time frame: Baseline, and sessions 1 - 3 (up to 30 days)

  5. Change in Mood (Alcohol)

    The short form of the Profile of Mood States. The POMS-SF uses five-point scales (Not at All to Extremely) to measure six aspects of mood (Tension or Anxiety, Anger or Hostility, Vigor or Activity, Fatigue or Inertia, Depression or Dejection, Confusion or Bewilderment).

    Time frame: Baseline, and sessions 1 - 3 (up to 30 days)

Secondary outcomes

  1. Change in Heart Rate (Stress)

    Time frame: Baseline, sessions 1 - 3, and follow up visit (up to 34 days)

  2. Change in Heart Rate (Alcohol)

    Time frame: Baseline, sessions 1 - 3, and follow up visit (up to 34 days)

  3. Change in blood pressure (stress)

    Time frame: Baseline, sessions 1 - 3, and follow up visit (up to 34 days)

  4. Change in blood pressure (alcohol)

    Time frame: Baseline, sessions 1 - 3, and follow up visit (up to 34 days)

  5. Change in motor coordination

    Motor coordination will be measured using a grooved pegboard task during the alcohol intervention. Participants place pegs into keyhole-shaped holes. Participants are required to pick up pegs one at a time and place them in holes. time to complete a trial will be measured. The test consists of four trials, and the time to complete each of the trials will be averaged to calculate the measure of motor coordination.

    Time frame: Baseline, and sessions 1 - 3 (up to 30 days)]

  6. Change in blood alcohol concentration

    Blood alcohol levels will be measured before and after administration of the alcohol dose.

    Time frame: Baseline, and sessions 1 - 3 (up to 30 days)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2025 (actual). Primary completion is estimated for Jul 2028, 41 months after the start.

Of 75 phase 1 interventional studies under Alcoholism, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 48. This study's planned 41 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2024
First posted
Dec 2, 2024
StartActual
Feb 1, 2025
Primary completionEst.
Jul 31, 2028
CompletionEst.
Jul 31, 2028
Last update
Sep 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06712602
Lead sponsor
Pop Test Oncology LLC
Responsible party
Sponsor
First posted
Dec 2, 2024
Start date
Feb 1, 2025
Primary completion
Jul 31, 2028 (estimated)
Completion
Jul 31, 2028 (estimated)
Last update
Sep 16, 2026

Study contacts

Mark Fillmore, PhD
Contact
Fillmore@uky.edu
859-257-4728
Kelsey Padgett, PhD
Contact
Ktpa223@uky.edu
859-257-5794
Mark Fillmore, PhD
principal investigator · Uiversity of Kentucky

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Org-34517

Start the discussion